If the Food and Drug Administration (FDA) approves the prostate cancer vaccine manufactured by the Dendreon Corporatin, it would be the first ever for an immunotherapy drug for any type of cancer. ?Prostate Cancer is a big problem. It is now the most common noncontainous cancer in the United States . And now we have over half million men in the U.S. with prostate cancer,? says President and CEO, Michael H. Gold, MD. The Seattle based company, has created a technology that uses a patient?s own blood cells to target invading cancer cells. ?We have found a way to reeducate the immune system and kill those cancer cells,? explained Gold citing Dendreon?s research using an active cellular immunotherapy technology. The vaccine is actually introduced in the latter stages of prostate cancer, which gives immeasurable hope to those who aren?t diagnosed in the earlier stages. And unlike most therapies offered today in the presence of prostate cancer, those taking Dendreon?s PROVENGE experienced no hair loss, fatigue, nausea, vomiting or infections.

As Gold addressed those at the Second Annual African American Summit, he pleaded with Black males ?to get more involved in clinical trials.? Without the African American representation in clinical trials, the data can?t be compiled that would assist with education and outreach in the Black communities.

?There are two types of people in the world: those who accept the world as it ? and then there are people like Tom (Farrington) and people like myself and all of you who believe that they can make a change.? Gold spoke volumes on the progress in the field of immunotherapy. ?One thing I like about PHEN, very much is that it is very focused on representing the patient. Tom (Farrington) and I are in it for the right reasons, which is to change cancer?, Gold added.

PHEN,Inc. © 2023 All rights reserved